pkcβ

PKCβ inhibitor 1 (KUN79359)(KUN79359) is a potent, selective and ATP-competitive inhibitor of PKC isozymes(IC50s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively).

PKC β pseudosubstrate acetate (PKC β pseudosubstrate acetate (172308-76-8 Free base)) is a cell-permeable, selective peptide inhibitor of PKC β. PKC β pseudosubstrate acetate can be used for in vivo and in vitro studies of the PKC β signaling pathway.

PKC-IN-1 is an ATP-competitive and reversible conventional PKC enzymes inhibitor (PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε with IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM, respectively).

Go 6983 is a PKC inhibitor with IC50 values of 7, 7, 6, 10, and 60 nM for PKCα, PKCβ, PKCγ, PKCδ, and PKCζ, respectively. Go 6983 has antitumor activity, cardiovascular protection, and protein kinase C inhibition.

Rottlerin (NSC-56346) is a natural product purified from Mallotus Philippinensis and is a specific PKC inhibitor (IC50: PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM). Rottlerin causes apoptosis via caspase 3 activation.

Enzastaurin (LY317615) (LY317615) is an effective PKCβ selective inhibitor (IC50: 6 nM), 6- to 20-fold selectivity against PKCα/γ/ε.

Hispidin is a polyphenol originally, including antioxidant, anti-inflammatory, and cytoprotective properties

PKCβII Peptide Inhibitor I, a specific PKCβII inhibitor, exhibits cardioprotective properties in a rat cardiac ischemia/reperfusion injury model and mitigates vascular endothelial dysfunction [1].

Myr-Tat-PKCβII is a cell-permeable peptide inhibitor of protein kinase C β II (PKCβII). It reduces the production of reactive oxygen species in ischemia-reperfusion injury in isolated rats and in vivo in pigs.

PKC ζ pseudosubstrate acetate is an inhibitor of protein kinase C (PKC) ζ; attached to cell permeabilisation Antennapedia domain vector peptide. Consists of amino acids 113 - 129 of PKC ζ pseudosubstrate domain linked by a disulphide bridge to the Antenna

PKC β pseudosubstrate TFA is a selective, cell-permeable inhibitor of PKC [1].

PKC-theta inhibitor 1 is an inhibitor of PKCθ (Ki of 6 nM)

PKCTheta-IN-2 (compound 14) is a potent and selective PKCθ inhibitor (IC50 = 0.25 nM) that suppresses IL-2 production in mice (IC50 = 682 nM).

PKC-IN-5 (Compound PKCe2054) is a protein kinase C (PKC) inhibitor that disrupts the interaction between PKCe and its anchoring protein RACK2.

PKC-IN-7 is an inhibitor of PKC and can be utilized in research related to diseases such as cancer.

PKC fragment (530-558) is a peptide fragment of protein kinase C (PKC) and is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption.

PKCε Inhibitor Peptide acetate is a selective PKCε inhibitor containing the site for its specific receptor for activated C kinase (RACK). PKCε Inhibitor Peptide acetate inhibits the translocation of PKCε, but not α-, β-, and δPKC.

PKC-theta inhibitor is PKC-θinhibitor, with an IC50 of 12 nM.

PKC-theta inhibitor hcl is a selective PKC-θinhibitor(IC50:12 nM).

PKC-IN-4 (compound 7l) is a highly potent and orally active inhibitor of atypical protein kinase C (aPKC), with an IC 50 value of 0.52 µM. In vitro studies show that PKC-IN-4 effectively suppresses NF-κB activity induced by TNF-α and impedes retinal vasculature permeability induced by both VEGF and TNF-α. [1]

Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of Aurora A (AurA) and PKC (α, β1, β2, θ), exhibiting inhibitory activity on AurA (IC50: 6.9 nM) and PKCα (IC50: 16.9 nM), and demonstrating anti-proliferative and anti-metastatic effects on breast cancer cells.

PKC-9 is a PKC-zeta inhibitor 9.

PKCδ Peptide Substrate is a highly specific substrate for the δ-type of Protein kinase C, composed of a sequence that mirrors murine eEF-1α (422-443) and includes Thr-431 [1].

PKCε (85-92) (ψεRACK) is a peptide and selective PKCε activator that does not affect the activity of other PKC isozymes.PKCε (85-92) induces a pro-angiogenic response in endothelial cells, promotes FGF-2 cytosolization, and regulates VEGF activity.